Novartis AG shares slumped after the drugmaker reported earnings that came short of analysts’ estimates on weak revenue from Pluvicto, a prostate cancer treatment that faced supply constraints.
Novartis Shares Drop on Weak Prostate Cancer Drug Sales
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.